Avicanna Announces United States Patent and Trademark Office Issuance of Patent on Topical Technology

USPTO issues Patent No. US 20230025693A1 (“Patent”) that covers Avicanna’s deep penetrating topical
cannabinoid composition and methods for treating musculoskeletal inflammation and pain

TORONTO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce the United States Patent and Trademark Office (“USPTO”) issuance of the Patent covering Avicanna’s deep penetrating topical cannabinoid composition and methods for treating musculoskeletal inflammation and pain.

“We are very happy with the issuance of another USPTO patent, this time on transdermal topical technology that has been a significant part of our research & development, R&D and clinical efforts. This technology was created through years of development, including AI guided prediction modelling, pre-clinical trials and real-world evidence and is part of our RHO Phyto commercial portfolio. We look forward to the incorporation of our patented technologies as we move forward to further evolving our pipeline, particularly those that target musculoskeletal pain and inflammation,” stated Aras Azadian, CEO.

Although various drugs are currently available to alleviate pain, they are associated with various debilitating side effects. Topical formulations can potentially provide pain relief, in particular improved formulations for the delivery of active ingredients directly into the deep layers of tissue to provide better efficacy and reduced gastro-intestinal, central nervous system and cardiovascular side effects.

The patented technology demonstrated further significance through the results of real-world evidence study where the study participants self-reported improvements in symptoms and quality of life in patients with musculoskeletal pain and inflammation. The study saw seventy-one patients complete baseline testing and a follow up after one month including two standardized symptom questionnaires with demographic, medical history, medication use. The study evaluated patient-reported efficacy of the RHO Phyto CBG Transdermal Gel containing 2% cannabidiol and 1% Cannabigerol on a range of clinical conditions including arthritis, osteoarthritis, rheumatoid arthritis, fibromyalgia, muscle and joint pain, localized pain, muscular and structural injuries, and post-surgical pain.